Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2018 | Combination therapies in CLL: ibrutinib and venetoclax

Stephen Devereux • 16 Apr 2018
BSH 2018
Chronic Lymphocytic Leukemia Ibrutinib Venetoclax

There has been a multitude of novel, exciting therapies within the field of chronic lymphocytic leukemia (CLL), explains Stephen Devereux, FRCP, FRCPath, PhD, of King’s College Hospital NHS Foundation Trust, London, UK. At the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK, Prof. Devereux discusses the CLARITY trial (ISCRTN13751862), exploring a combination of ibrutinib and venetoclax, and the promise that this may in the future result in a curative therapy for certain patients.

More from Stephen Devereux

1:12
BSH 2018: interdisciplinary highlights
Stephen Devereux • 16 Apr 2018
2:31
Exploiting the tumor microenvironment for B-cell maliganancy treatment
Stephen Devereux • 16 Apr 2018

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals